2012-10-09T09:03:28+02:00 Marit Einejord http://www.unn.no/klinisk-farmakologi/category8846.html tag:www.unn.no,2012-10-09:/klinisk-farmakologi/lamotrigin-i-serum-article97833-8846.html 2012-10-09T09:03:28+02:00 Bente Helene Johnsen <p> &nbsp;</p> <table border="1" cellpadding="0" cellspacing="0"> <tbody> <tr> <td> <p> <strong>Laboratorium</strong></p> </td> <td> <p> <strong>Fagområdet Klinisk farmakologi, </strong><br /> <strong>Laboratoriemedisin, </strong><br /> <strong>Universitetssykehuset Nord-Norge, 9038 Tromsø.</strong></p> <p> <strong>Tlf. 776 26718</strong><strong>(prøvesvar)<br /> <strong>Tlf. 776 26706</strong><strong>(lege- og rusmiddelanalyser)&nbsp;</strong></strong></p> </td> </tr> <tr> <td> <p> <strong>Prøvemateriale</strong></p> </td> <td> <p> <strong>Serum</strong></p> </td> </tr> <tr> <td> <p> <strong>Mengde</strong></p> </td> <td> <p> <strong>0,5 mL </strong></p> </td> </tr> <tr> <td> <p> <strong>Prøvetakingsrutiner</strong></p> </td> <td> <p> <strong><u>Pasientforberedelse </u></strong><br /> <strong>Prøven tas like før neste dose, dvs ca 12 timer etter siste dose </strong><strong>ved dosering x2 per dag og ca 24 timer etter siste dose ved dosering x1 per dag.&nbsp; Prøven tas ved stabil likevekt, dvs </strong><strong>minst 6 dager etter oppstart eller doseendring.</strong></p> <p> <strong><u>Prøvetaking </u></strong><br /> <strong>Bruk glass uten gel. Serum avpipetteres og oppbevares kjølig før forsendelse.</strong></p> </td> </tr> <tr> <td> <p> <strong>Analysedag</strong><strong>(er)</strong></p> </td> <td> <p> <strong>Tirsdag og torsdag</strong></p> </td> </tr> <tr> <td> <p> <strong>Referanseområde</strong></p> </td> <td> <p> <strong>10-50 &mu;mol/L. </strong></p> <p> <strong>Gjelder forebygging av epileptiske anfall. For bipolar lidelse kan klinisk effekt oppnås ved lavere konsentrasjoner</strong></p> </td> </tr> <tr> <td> <p> <strong>VKa</strong><strong>(analytisk variasjon)</strong></p> </td> <td> <p> &nbsp;</p> </td> </tr> <tr> <td> <p> <strong>Viktigste indikasjoner</strong></p> </td> <td> <p> <strong>Terapikontroll, vurdering av compliance, bivirkninger og interaksjoner, samt intoksikasjonsutredning.</strong></p> </td> </tr> <tr> <td> <p> <strong>Farmakologiske data</strong></p> </td> <td> <p> <strong>Molekylvekt 256. Biologisk tilgjengelighet: 98 %. T_max: 2-3 t. T</strong><strong>_1/2</strong><strong>: 33 t gjennomsnittlig, men med stor variasjon. Elimineres hovedsaklig ved metabolisme i lever. </strong></p> </td> </tr> <tr> <td> <p> <strong>Tolkning</strong></p> </td> <td> <p> <strong>De fleste pasienter vil ha klinisk signifikante bivirkninger ved konsentrasjoner &gt; 40 &mu;mol/L. Tegn på overdosering kan være kvalme, svimmelhet, ataksi, koordinasjonsproblemer, søvnighet og synsforstyrrelser</strong><strong>.</strong></p> </td> </tr> </tbody> </table> tag:www.unn.no,2012-06-20:/klinisk-farmakologi/etylglukuronid-etg-etylsulfat-ets-i-urin-article95185-8846.html 2012-06-20T16:37:26+02:00 Bente Helene Johnsen <p> &nbsp;</p> <p> &nbsp;</p> <table border="1" cellpadding="2" width="89%"> <tbody> <tr> <td> <strong><strong>Laboratorium</strong></strong></td> <td> <p> Fagområdet Klinisk farmakologi, Laboratoriemedisin,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Universitetssykehuset Nord-Norge, 9038 Tromsø.</p> <p> Tlf. 776 26718 (prøvesvar)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<br /> Tlf. 776 26706 (farmakologiske- og rusanalyser<strong>)</strong></p> </td> </tr> <tr> <td> <strong>Prøvemateriale</strong></td> <td> <br /> Urin<br /> &nbsp;</td> </tr> <tr> <td> <strong>Mengde</strong></td> <td> <p> minimum 1 mL</p> </td> </tr> <tr> <td> <strong>Prøvetakingsrutiner</strong></td> <td> <u>Pasientforberedelse:</u><br /> Ingen<br /> <u>Prøvetaking: </u><br /> Prøven fordeles på to glass (Urin Monovette-rør). Oppbevares kjølig før forsendelse.</td> </tr> <tr> <td> <strong>Analysedag(er)</strong></td> <td> Torsdag</td> </tr> <tr> <td> <strong>Referanseområde</strong></td> <td> NEG (negativ)</td> </tr> <tr> <td> <strong>VKa (analytisk variasjon)</strong></td> <td> &nbsp;</td> </tr> <tr> <td> <strong>Viktigste indikasjoner</strong></td> <td> <p> Påvisning av nylig inntak av alkohol (etanol).&nbsp;</p> </td> </tr> <tr> <td> <strong>Tolkning</strong></td> <td> <p> Etylglukuronid og etylsulfat er metabolitter av etanol som kan påvises i urin i lengre tid enn etanol selv.&nbsp; Etanol kan normalt påvises i urin inntil 12 timer etter inntak, mens metabolittene kan påvises inntil 48 timer etter moderat inntak (3-4 enheter) og over 100 timer etter stort etanolinntak.</p> </td> </tr> <tr> <td> <strong>Referanser</strong></td> <td> &nbsp;</td> </tr> </tbody> </table> tag:www.unn.no,2008-11-07:/klinisk-farmakologi/blodrekvisisjon-article60068-8846.html 2008-11-07T15:09:11+01:00 Åshild Halvorsen

Klinisk farmakologisk avdeling.

<a href="http://www.unn.no/getfile.php/UNN-Internett/Enhet/Klinisk%20farmakologisk/Dokumenter/blodrekvisisjon.pdf" >Blodrekvisisjon</a><br /> tag:www.unn.no,2008-11-07:/klinisk-farmakologi/rusmiddelanalyser-rekvisisjonsskjema-article60067-8846.html 2008-11-07T15:05:13+01:00 Åshild Halvorsen

Klinisk farmakologisk avdeling.

<a href="http://www.unn.no/getfile.php/UNN-Internett/Fagfolk/Labhandbok/Dokumenter/Rekvisisjon_rusmiddelanalyser.pdf" >Rekvisisjon</a><br /> tag:www.unn.no,2008-10-02:/laboratoriehaandbok/klorprotiksen-article59077-14289.html 2008-10-02T14:14:33+02:00 Åshild Halvorsen <p>&#160;</p> <table cellpadding="2" width="89%" border="1"> <tbody> <tr> <td width="40%"><strong>Laboratorium</strong></td> <td width="60%">Laboratoriemedisin, Universitetssykehuset Nord-Norge, 9038 Tromsø,&#160;Klinisk farmakologi, tlf 77626706</td> </tr> <tr> <td width="40%"><strong>Materiale</strong></td> <td width="60%"> <p><span>Serum&#160;uten gel.</span></p> </td> </tr> <tr> <td width="40%"><strong>Mengde</strong></td> <td width="60%"><span>0,5 mL</span></td> </tr> <tr> <td width="40%"><strong>Prøvebehandling</strong></td> <td width="60%">Serum avpipetteres før forsendelse/ analysering</td> </tr> <tr> <td width="40%"><strong>Referanseområde/ terapeutisk område</strong></td> <td width="60%"> <p>&#160;150 - 1000 nmol/L</p> </td> </tr> <tr> <td width="40%"><strong>VKa (analyttisk variasjon):</strong></td> <td width="60%">&#160;</td> </tr> <tr> <td width="40%"><strong>Viktigste indikasjoner</strong></td> <td width="60%">&#160;</td> </tr> <tr> <td width="40%"><strong>Tolkning</strong></td> <td width="60%">&#160;</td> </tr> <tr> <td width="40%"><strong>Referanser</strong></td> <td width="60%"> <p>&#160;</p> </td> </tr> </tbody> </table> <p>&#160;</p> <p>&#160;</p> tag:www.unn.no,2008-08-06:/laboratoriehaandbok/zolpidem-article57428-14289.html 2008-08-06T13:00:35+02:00 Åshild Halvorsen <p>&#160;</p> <table cellpadding="2" width="89%" border="1"> <tbody> <tr> <td width="241"><strong>Laboratorium</strong></td> <td width="371">Laboratoriemedisin, Universitetssykehuset Nord-Norge, 9038 Tromsø. Klinisk farmakologi tlf. 77626706</td> </tr> <tr> <td width="241"><strong>Materiale</strong></td> <td width="371"> <p><span>Serum&#160;uten gel</span></p> </td> </tr> <tr> <td width="241"><strong>Mengde</strong></td> <td width="371"><span>0,5 mL</span></td> </tr> <tr> <td width="241"><strong>Prøvebehandling</strong></td> <td width="371">Serum avpipetteres før forsendelse/ analysering</td> </tr> <tr> <td width="241"><strong>Referanseområde/ terapeutisk område</strong></td> <td width="371"> <p>&#160;</p> </td> </tr> <tr> <td width="241"><strong>VKa (analyttisk variasjon):</strong></td> <td width="371">&#160;</td> </tr> <tr> <td width="241"><strong>Viktigste indikasjoner</strong></td> <td width="371">&#160;</td> </tr> <tr> <td width="241"><strong>Tolkning</strong></td> <td width="371">&#160;</td> </tr> <tr> <td width="241"><strong>Referanser</strong></td> <td width="371"> <p>&#160;</p> </td> </tr> </tbody> </table> <p>&#160;</p> tag:www.unn.no,2008-08-06:/laboratoriehaandbok/amiodaron-article57430-14289.html 2008-08-06T13:16:10+02:00 Åshild Halvorsen <p>&#160;Preparatnavn: Cordarone</p> <table cellpadding="2" width="89%" border="1"> <tbody> <tr> <td width="40%"><strong>Laboratorium</strong></td> <td width="60%">Laboratoriemedisin, Universitetssykehuset Nord-Norge, 9038 Tromsø. Klinisk&#160;farmakologi tlf. 77626706</td> </tr> <tr> <td width="40%"><strong>Materiale</strong></td> <td width="60%"> <p><span>Serum&#160;uten gel</span></p> </td> </tr> <tr> <td width="40%"><strong>Mengde</strong></td> <td width="60%"><span>0,5 mL</span></td> </tr> <tr> <td width="40%"><strong>Prøvebehandling</strong></td> <td width="60%">Serum avpipetteres før forsendelse/ analysering</td> </tr> <tr> <td width="40%"><strong>Referanseområde/ terapeutisk område</strong></td> <td width="60%"> <p><span>1,5 -3,7 µmol/L ved behandling av ventrikulære arytmier. Lavere konsentrasjon ved andre indikasjoner.</span></p> </td> </tr> <tr> <td width="40%"><strong>VKa (analyttisk variasjon):</strong></td> <td width="60%">&#160;</td> </tr> <tr> <td width="40%"><strong>Viktigste indikasjoner</strong></td> <td width="60%"> <p><span>Antiarytmikum.</span><br /> <span>Legemiddel med særlig lang halveringstid. Doseres høyere i starten (ofte i.v.) enn under vedlikehold.</span><br /> <span><span><br /> Metaboliseres til desetylamiodaron.</span> Hovedmetabolitten desetylamiodaron er kardioaktiv, men inngår ikke i referanseområdet.<br /> <span>Økt risiko for alvorlige arytmier</span><span> ved kombinasjon med andre legemidler med effekt på hjertets impulsgenerering og ledning.</span></span></p> </td> </tr> <tr> <td width="40%"><strong>Tolkning</strong></td> <td width="60%"> <p>&#160;</p> </td> </tr> <tr> <td width="40%"><strong>Referanser</strong></td> <td width="60%"> <p>&#160;</p> </td> </tr> </tbody> </table> <p>&#160;</p> <table cellpadding="2" width="89%" border="1"> <tbody> <tr> </tr> </tbody> </table> <p>&#160;</p> <p>&#160;</p> tag:www.unn.no,2008-08-01:/laboratoriehaandbok/fentanyl-i-urin-article57307-14289.html 2008-08-01T14:12:54+02:00 Åshild Halvorsen <p>&#160;</p> <table cellpadding="2" width="89%" border="1"> <tbody> <tr> <td width="40%"><strong>Laboratorium</strong></td> <td width="60%">Laboratoriemedisin, Universitetssykehuset Nord-Norge, 9038 Tromsø.&#160;Klinisk farmakologi tlf. 77626706</td> </tr> <tr> <td width="40%"><strong>Materiale</strong></td> <td width="60%"> <p><span>Urin</span></p> </td> </tr> <tr> <td width="40%"><strong>Mengde</strong></td> <td width="60%"><span>1&#160;mL</span></td> </tr> <tr> <td width="40%"><strong>Prøvebehandling</strong></td> <td width="60%">&#160;</td> </tr> <tr> <td width="40%"><strong>Referanseområde/ terapeutisk område</strong></td> <td width="60%"> <p>&#160;</p> </td> </tr> <tr> <td width="40%"><strong>VKa (analyttisk variasjon):</strong></td> <td width="60%">&#160;</td> </tr> <tr> <td width="40%"><strong>Viktigste indikasjoner</strong></td> <td width="60%">&#160;</td> </tr> <tr> <td width="40%"><strong>Tolkning</strong></td> <td width="60%">&#160;</td> </tr> <tr> <td width="40%"><strong>Referanser</strong></td> <td width="60%"> <p>&#160;</p> </td> </tr> </tbody> </table> <p>&#160;</p> tag:www.unn.no,2008-08-01:/laboratoriehaandbok/heroin-i-urin-article57308-14289.html 2008-08-01T14:14:23+02:00 Åshild Halvorsen <p>&#160;</p> <table cellpadding="2" width="89%" border="1"> <tbody> <tr> <td width="40%"><strong>Laboratorium</strong></td> <td width="60%">Laboratoriemedisin, Universitetssykehuset Nord-Norge, 9038 Tromsø.&#160;Klinisk farmakologi tlf. 77626706</td> </tr> <tr> <td width="40%"><strong>Materiale</strong></td> <td width="60%"> <p><span>Urin</span></p> </td> </tr> <tr> <td width="40%"><strong>Mengde</strong></td> <td width="60%"><span>1 mL</span></td> </tr> <tr> <td width="40%"><strong>Prøvebehandling</strong></td> <td width="60%">&#160;</td> </tr> <tr> <td width="40%"><strong>Referanseområde/ terapeutisk område</strong></td> <td width="60%"> <p>&#160;</p> </td> </tr> <tr> <td width="40%"><strong>VKa (analyttisk variasjon):</strong></td> <td width="60%">&#160;</td> </tr> <tr> <td width="40%"><strong>Viktigste indikasjoner</strong></td> <td width="60%">&#160;</td> </tr> <tr> <td width="40%"><strong>Tolkning</strong></td> <td width="60%">&#160;</td> </tr> <tr> <td width="40%"><strong>Referanser</strong></td> <td width="60%"> <p>&#160;</p> </td> </tr> </tbody> </table> <p>&#160;</p> tag:www.unn.no,2008-08-01:/laboratoriehaandbok/benzoylecgonin-i-urin-article57309-14289.html 2008-08-01T14:15:50+02:00 Åshild Halvorsen <p>&#160;</p> <table cellpadding="2" width="89%" border="1"> <tbody> <tr> <td width="40%"><strong>Laboratorium</strong></td> <td width="60%"> <p>Laboratoriemedisin, Universitetssykehuset Nord-Norge, 9038 Tromsø. Klinisk&#160;farmakologi tlf. 77626706</p> </td> </tr> <tr> <td width="40%"><strong>Materiale</strong></td> <td width="60%"> <p><span>Urin</span></p> </td> </tr> <tr> <td width="40%"><strong>Mengde</strong></td> <td width="60%"><span>1 mL</span></td> </tr> <tr> <td width="40%"><strong>Prøvebehandling</strong></td> <td width="60%">&#160;</td> </tr> <tr> <td width="40%"><strong>Referanseområde/ terapeutisk område</strong></td> <td width="60%"> <p>&#160;</p> </td> </tr> <tr> <td width="40%"><strong>VKa (analyttisk variasjon):</strong></td> <td width="60%">&#160;</td> </tr> <tr> <td width="40%"><strong>Viktigste indikasjoner</strong></td> <td width="60%">&#160;</td> </tr> <tr> <td width="40%"><strong>Tolkning</strong></td> <td width="60%">&#160;</td> </tr> <tr> <td width="40%"><strong>Referanser</strong></td> <td width="60%"> <p>&#160;</p> </td> </tr> </tbody> </table> <p>&#160;</p> tag:www.unn.no,2008-08-01:/laboratoriehaandbok/ecstacy-mdma-article57310-14289.html 2008-08-01T14:44:38+02:00 Åshild Halvorsen <p>&#160;</p> <table cellpadding="2" width="89%" border="1"> <tbody> <tr> <td width="40%"><strong>Laboratorium</strong></td> <td width="60%"> <p>Laboratoriemedisin, Universitetssykehuset Nord-Norge, 9038 Tromsø.&#160;Klinisk farmakologi tlf. 77626706</p> </td> </tr> <tr> <td width="40%"><strong>Materiale</strong></td> <td width="60%"> <p><span>Serum uten gel.</span></p> </td> </tr> <tr> <td width="40%"><strong>Mengde</strong></td> <td width="60%"><span>0,5 mL</span></td> </tr> <tr> <td width="40%"><strong>Prøvebehandling</strong></td> <td width="60%">Serum avpipetteres før forsendelse/ analysering</td> </tr> <tr> <td width="40%"><strong>Referanseområde/ terapeutisk område</strong></td> <td width="60%"> <p>&#160;</p> </td> </tr> <tr> <td width="40%"><strong>VKa (analyttisk variasjon):</strong></td> <td width="60%">&#160;</td> </tr> <tr> <td width="40%"><strong>Viktigste indikasjoner</strong></td> <td width="60%">&#160;</td> </tr> <tr> <td width="40%"><strong>Tolkning</strong></td> <td width="60%">&#160;</td> </tr> <tr> <td width="40%"><strong>Referanser</strong></td> <td width="60%"> <p>&#160;</p> </td> </tr> </tbody> </table> <p>&#160;</p> tag:www.unn.no,2008-08-01:/laboratoriehaandbok/ecstacy-mdma-i-urin-article57311-14289.html 2008-08-01T14:46:05+02:00 Åshild Halvorsen <p>&#160;</p> <table cellpadding="2" width="89%" border="1"> <tbody> <tr> <td width="40%"><strong>Laboratorium</strong></td> <td width="60%">Laboratoriemedisin, Universitetssykehuset Nord-Norge, 9038 Tromsø.&#160;Klinisk&#160;farmakologi tlf. 77626706</td> </tr> <tr> <td width="40%"><strong>Materiale</strong></td> <td width="60%"> <p><span>Urin</span></p> </td> </tr> <tr> <td width="40%"><strong>Mengde</strong></td> <td width="60%"><span>1mL</span></td> </tr> <tr> <td width="40%"><strong>Prøvebehandling</strong></td> <td width="60%">&#160;</td> </tr> <tr> <td width="40%"><strong>Referanseområde/ terapeutisk område</strong></td> <td width="60%"> <p>&#160;</p> </td> </tr> <tr> <td width="40%"><strong>VKa (analyttisk variasjon):</strong></td> <td width="60%">&#160;</td> </tr> <tr> <td width="40%"><strong>Viktigste indikasjoner</strong></td> <td width="60%">&#160;</td> </tr> <tr> <td width="40%"><strong>Tolkning</strong></td> <td width="60%">&#160;</td> </tr> <tr> <td width="40%"><strong>Referanser</strong></td> <td width="60%"> <p>&#160;</p> </td> </tr> </tbody> </table> <p>&#160;</p> tag:www.unn.no,2008-08-01:/laboratoriehaandbok/diazepam-i-urin-article57312-14289.html 2008-08-01T14:48:18+02:00 Åshild Halvorsen <p>&#160;</p> <table cellpadding="2" width="89%" border="1"> <tbody> <tr> <td width="40%"><strong>Laboratorium</strong></td> <td width="60%">Laboratoriemedisin, Universitetssykehuset Nord-Norge, 9038 Tromsø.&#160;Klinisk farmakologi tlf. 77626706</td> </tr> <tr> <td width="40%"><strong>Materiale</strong></td> <td width="60%"> <p><span>Urin</span></p> </td> </tr> <tr> <td width="40%"><strong>Mengde</strong></td> <td width="60%"><span>1mL</span></td> </tr> <tr> <td width="40%"><strong>Prøvebehandling</strong></td> <td width="60%">&#160;</td> </tr> <tr> <td width="40%"><strong>Referanseområde/ terapeutisk område</strong></td> <td width="60%"> <p>&#160;</p> </td> </tr> <tr> <td width="40%"><strong>VKa (analyttisk variasjon):</strong></td> <td width="60%">&#160;</td> </tr> <tr> <td width="40%"><strong>Viktigste indikasjoner</strong></td> <td width="60%">&#160;</td> </tr> <tr> <td width="40%"><strong>Tolkning</strong></td> <td width="60%">&#160;</td> </tr> <tr> <td width="40%"><strong>Referanser</strong></td> <td width="60%"> <p>&#160;</p> </td> </tr> </tbody> </table> <p>&#160;</p> tag:www.unn.no,2008-08-01:/laboratoriehaandbok/flunitrazepam-i-urin-article57313-14289.html 2008-08-01T14:49:36+02:00 Åshild Halvorsen <p>&#160;</p> <table cellpadding="2" width="89%" border="1"> <tbody> <tr> <td width="40%"><strong>Laboratorium</strong></td> <td width="60%">Laboratoriemedisin, Universitetssykehuset Nord-Norge, 9038 Tromsø.&#160;Klinisk farmakologi tlf. 77626706</td> </tr> <tr> <td width="40%"><strong>Materiale</strong></td> <td width="60%"> <p><span>Urin</span></p> </td> </tr> <tr> <td width="40%"><strong>Mengde</strong></td> <td width="60%"><span>1mL</span></td> </tr> <tr> <td width="40%"><strong>Prøvebehandling</strong></td> <td width="60%">&#160;</td> </tr> <tr> <td width="40%"><strong>Referanseområde/ terapeutisk område</strong></td> <td width="60%"> <p>&#160;</p> </td> </tr> <tr> <td width="40%"><strong>VKa (analyttisk variasjon):</strong></td> <td width="60%">&#160;</td> </tr> <tr> <td width="40%"><strong>Viktigste indikasjoner</strong></td> <td width="60%">&#160;</td> </tr> <tr> <td width="40%"><strong>Tolkning</strong></td> <td width="60%">&#160;</td> </tr> <tr> <td width="40%"><strong>Referanser</strong></td> <td width="60%"> <p>&#160;</p> </td> </tr> </tbody> </table> <p>&#160;</p> tag:www.unn.no,2008-08-01:/laboratoriehaandbok/desmetyldoxepin-article57316-14289.html 2008-08-01T14:56:55+02:00 Åshild Halvorsen <p>&#160;</p> <table cellpadding="2" width="89%" border="1"> <tbody> <tr> <td width="40%"><strong>Laboratorium</strong></td> <td width="60%">Laboratoriemedisin, Universitetssykehuset Nord-Norge, 9038 Tromsø. Klinisk farmakologi tlf. 77626706</td> </tr> <tr> <td width="40%"><strong>Materiale</strong></td> <td width="60%"> <p><span>Serum&#160;uten gel.</span></p> </td> </tr> <tr> <td width="40%"><strong>Mengde</strong></td> <td width="60%"><span>0,5 mL</span></td> </tr> <tr> <td width="40%"><strong>Prøvebehandling</strong></td> <td width="60%">Serum avpipetteres før forsendelse/ analysering</td> </tr> <tr> <td width="40%"><strong>Referanseområde/ terapeutisk område</strong></td> <td width="60%"> <p>&#160;</p> </td> </tr> <tr> <td width="40%"><strong>VKa (analyttisk variasjon):</strong></td> <td width="60%">&#160;</td> </tr> <tr> <td width="40%"><strong>Viktigste indikasjoner</strong></td> <td width="60%">&#160;</td> </tr> <tr> <td width="40%"><strong>Tolkning</strong></td> <td width="60%">&#160;</td> </tr> <tr> <td width="40%"><strong>Referanser</strong></td> <td width="60%"> <p>&#160;</p> </td> </tr> </tbody> </table> <p>&#160;</p> tag:www.unn.no,2008-08-01:/laboratoriehaandbok/klorpromazin-7-oh-article57318-14289.html 2008-08-01T15:07:55+02:00 Åshild Halvorsen <p>&#160;</p> <table cellpadding="2" width="89%" border="1"> <tbody> <tr> <td width="40%"><strong>Laboratorium</strong></td> <td width="60%">Laboratoriemedisin Universitetssykehuset Nord-Norge, 9038 Tromsø, Klinisk farmakologi tlf 77626706</td> </tr> <tr> <td width="40%"><strong>Materiale</strong></td> <td width="60%"> <p><span>Serum fra glass uten gel.</span></p> </td> </tr> <tr> <td width="40%"><strong>Mengde</strong></td> <td width="60%"><span>0,5 mL</span></td> </tr> <tr> <td width="40%"><strong>Prøvebehandling</strong></td> <td width="60%">&#160;</td> </tr> <tr> <td width="40%"><strong>Referanseområde/ terapeutisk område</strong></td> <td width="60%"> <p>&#160;</p> </td> </tr> <tr> <td width="40%"><strong>VKa (analyttisk variasjon):</strong></td> <td width="60%">&#160;</td> </tr> <tr> <td width="40%"><strong>Viktigste indikasjoner</strong></td> <td width="60%">&#160;</td> </tr> <tr> <td width="40%"><strong>Farmakologiske data</strong></td> <td width="60%">&#160;</td> </tr> <tr> <td width="40%"><strong>Referanser</strong></td> <td width="60%"> <p>&#160;</p> </td> </tr> </tbody> </table> <p>&#160;</p> tag:www.unn.no,2008-07-31:/laboratoriehaandbok/venlafaxin-article57296-14289.html 2008-07-31T14:00:51+02:00 Åshild Halvorsen <p>&#160;Preparatnavn: Efexor, Venlafaxin</p> <p>&#160;</p> <table cellpadding="2" width="89%" border="1"> <tbody> <tr> <td width="40%"><strong>Laboratorium</strong></td> <td width="60%">Laboratoriemedisin, Universitetssykehuset Nord-Norge, 9038 Tromsø.&#160;Klinisk farmakologi tlf. 77626706</td> </tr> <tr> <td width="40%"><strong>Materiale</strong></td> <td width="60%">Serum uten gel</td> </tr> <tr> <td width="40%"><strong>Mengde</strong></td> <td width="60%">0,5&#160;mL</td> </tr> <tr> <td width="40%"><strong>Prøvebehandling</strong></td> <td width="60%">Serum må avpipetteres før forsendelse/ analysering</td> </tr> <tr> <td width="40%"><strong>Referanseområde</strong></td> <td width="60%"> <p>180-1400 nmol/L (uten metabolitt)</p> </td> </tr> <tr> <td width="40%"><strong>VKa (analyttisk variasjon):</strong></td> <td width="60%">&#160;</td> </tr> <tr> <td width="40%"><strong>Viktigste indikasjoner</strong></td> <td width="60%">&#160;</td> </tr> <tr> <td width="40%"><strong>Tolkning</strong></td> <td width="60%">&#160;</td> </tr> <tr> <td width="40%"><strong>Referanser</strong></td> <td width="60%">&#160;</td> </tr> </tbody> </table> <o:p></o:p> <p>&#160;</p> tag:www.unn.no,2008-07-30:/laboratoriehaandbok/paracetamol-article57284-14289.html 2008-07-30T00:00:00+02:00 Åshild Halvorsen <div class="digest" id="cpart-ingress-17558-full"> &nbsp;</div> <div class="ctsitebase-articledisplay-body"> <p> &nbsp;</p> <table border="1" cellpadding="2" width="89%"> <tbody> <tr> <td width="40%"> <strong>Laboratorium</strong></td> <td width="60%"> Laboratoriemedisin, Universitetssykehuset Nord-Norge, 9038 Tromsø.&nbsp;Medisinsk biokjemi tlf. 77626728</td> </tr> <tr> <td width="40%"> <strong>Materiale</strong></td> <td width="60%"> Serum uten gel</td> </tr> <tr> <td width="40%"> <strong>Mengde</strong></td> <td width="60%"> 0,5&nbsp;mL</td> </tr> <tr> <td width="40%"> <strong>Prøvebehandling</strong></td> <td width="60%"> Serum må avpipetteres før forsendelse/ analysering</td> </tr> <tr> <td width="40%"> <strong>Referanseområde</strong></td> <td width="60%"> <p> 30 - 130&nbsp;<span style="font-size: 12pt; font-family: symbol; mso-ascii-font-family: 'times new roman'; mso-hansi-font-family: 'times new roman'; mso-char-type: symbol; mso-symbol-font-family: symbol"><span style="mso-char-type: symbol; mso-symbol-font-family: symbol">m<font face="Arial" size="2">mol/L ved terapeutisk bruk</font></span></span></p> </td> </tr> <tr> <td width="40%"> <strong>VKa (analyttisk variasjon):</strong></td> <td width="60%"> 5,9&nbsp;%</td> </tr> <tr> <td width="40%"> <strong>Viktigste indikasjoner</strong></td> <td width="60%"> Intoksikasjon</td> </tr> <tr> <td width="40%"> <strong>Tolkning</strong></td> <td width="60%"> <span style="font-size: 12pt; color: #454647; font-family: arial; mso-fareast-font-family: 'times new roman'; mso-bidi-language: ar-sa; mso-ansi-language: no-bok; mso-fareast-language: no-bok"><font color="#000000" size="2">Verdien må vurderes ut fra tid siden siste inntak. Farmakologisk vurdering følger alle svar</font></span></td> </tr> <tr> <td width="40%"> <strong>Referanser</strong></td> <td width="60%"> <a href="http://www.uus.no/brukerhandbok/index.asp?bok=2&amp;Kap=9&amp;unit=466&amp;par=289&amp;boknavn=BrukerhÃ¥ndbok%20i%20klinisk%20kjemi%202004">Brukerhåndbok Klinisk kjemi</a></td> </tr> </tbody> </table> </div> tag:www.unn.no,2008-04-18:/laboratoriehaandbok/rifampicin-article54708-14289.html 2008-04-18T12:50:05+02:00 Åshild Halvorsen <p>&#160;</p> <table cellpadding="2" width="89%" border="1"> <tbody> <tr> <td width="40%"><strong>Laboratorium</strong></td> <td width="60%">Laboratoriemedisin, Universitetssykehuset Nord-Norge, 9038 Tromsø.&#160;Klinisk farmakologi tlf. 77626706</td> </tr> <tr> <td width="40%"><strong>Materiale</strong></td> <td width="60%"> <p><span>Serum&#160;uten gel</span></p> </td> </tr> <tr> <td width="40%"><strong>Mengde</strong></td> <td width="60%"><span>0,5 mL</span></td> </tr> <tr> <td width="40%"><strong>Prøvebehandling</strong></td> <td width="60%">Serum avpipetteres, lysbeskyttes i aluminiumsfolie og fryses. Sendes frosset.</td> </tr> <tr> <td width="40%"><strong>Referanseområde/ terapeutisk område</strong></td> <td width="60%"> <p>&#160;</p> </td> </tr> <tr> <td width="40%"><strong>VKa (analyttisk variasjon):</strong></td> <td width="60%">&#160;</td> </tr> <tr> <td width="40%"><strong>Viktigste indikasjoner</strong></td> <td width="60%"> <p>&#160;</p> </td> </tr> <tr> <td width="40%"><strong>Tolkning</strong></td> <td width="60%"> <p>&#160;</p> </td> </tr> <tr> <td width="40%"><strong>Referanser</strong></td> <td width="60%"> <p>&#160;</p> </td> </tr> </tbody> </table> <p>&#160;</p> tag:www.unn.no,2007-12-19:/laboratoriehaandbok/metylfenidat-i-serum-article48866-14289.html 2007-12-19T08:00:00+01:00 Åshild Halvorsen <div> <table border="1" cellpadding="0" cellspacing="0"> <tbody> <tr> <td> <p> <strong>Laboratorium</strong></p> </td> <td> <p> Fagområdet Klinisk farmakologi,<br /> Laboratoriemedisin,<br /> Universitetssykehuset Nord-Norge, 9038 Tromsø.</p> <p> Tlf. 776 26718(prøvesvar)<br /> Tlf. 776 26706(legemiddel- og rusmiddelanalyser)</p> </td> </tr> <tr> <td> <p> <strong>Prøvemateriale</strong></p> </td> <td> <p> Serum</p> </td> </tr> <tr> <td> <p> <strong>Mengde</strong></p> </td> <td> <p> 0,5 mL</p> </td> </tr> <tr> <td> <p> <strong>Prøvetakingsrutiner</strong></p> </td> <td> <p> <u>Pasientforberedelse </u><br /> Tidspunkt for prøvetaking avhenger av administrasjonsform, se under Referanseområde.</p> <p> <u>Prøvetaking </u><br /> Bruk glass uten gel. Serum avpipetteres og oppbevares kjølig før forsendelse.</p> </td> </tr> <tr> <td> <p> <strong>Analysedag</strong><strong>(er)</strong></p> </td> <td> <p> Mandag</p> </td> </tr> <tr> <td> <p> <strong>Referanseområde</strong></p> </td> <td> <p> 10-70 nmol/L</p> <p> Referanseområdet gjelder prøver tatt:<br /> 1-2 timer etter inntak av tabletter (Ritalin/ Equasym/ Medikinet).<br /> Formuleringer med modifisert frisetting:<br /> 2-3 timer etter inntak av Medikinet depotkapsler.<br /> 4-6 timer etter inntak av Ritalin og Equasym depotkapsler.<br /> 6-8 timer etter inntak av Concerta depottabletter.</p> </td> </tr> <tr> <td> <p> <strong>VKa</strong><strong>(analytisk variasjon)</strong></p> </td> <td> <p> &nbsp;</p> </td> </tr> <tr> <td> <p> <strong>Viktigste indikasjoner</strong></p> </td> <td> <p> Terapikontroll, vurdering av etterlevelse, bivirkninger og interaksjoner, samt intoksikasjonsutredning.</p> </td> </tr> <tr> <td> <p> <strong>Farmakologiske data</strong></p> </td> <td> <p> Molekylvekt: 233. Biotilgjengelighet: ca. 30 %. T_max: 1-8 t, avhengig av administrasjonsform. T_1/2: ca 2 t. Mesteparten utskilles i urin som 2-fenyl-2-piperidyleddiksyre (60-86&nbsp;%). &lt;1 % utskilles uomdannet i urin.</p> </td> </tr> <tr> <td> <p> <strong>Tolkning</strong></p> </td> <td> <p> Akutt overdosering kan gi symptomer som oppkast, uro, skjelving, kramper (kan ledsages av koma), hallusinasjoner, delirium, svetting, rødming, hodepine, takykardi, palpitasjoner, hjertearytmier, hypertensjon, mydriasis og slimhinnetørrhet.</p> </td> </tr> </tbody> </table> </div> tag:www.unn.no,2007-12-18:/laboratoriehaandbok/ziprasidon-article39895-14289.html 2007-12-18T00:00:00+01:00 Åshild Halvorsen <p>&#160; Preparatnavn: Zeldox</p> <table cellpadding="2" width="89%" border="1"> <tbody> <tr> <td width="40%"><strong>Laboratorium</strong></td> <td width="60%">Laboratoriemedisin, Universitetssykehuset Nord-Norge, 9038 Tromsø.&#160;Klinisk farmakologi tlf. 77626706</td> </tr> <tr> <td width="40%"><strong>Materiale</strong></td> <td width="60%"> <p><span>Serum&#160;uten gel</span></p> </td> </tr> <tr> <td width="40%"><strong>Mengde</strong></td> <td width="60%"><span>0,5 mL</span></td> </tr> <tr> <td width="40%"><strong>Prøvebehandling</strong></td> <td width="60%">Serum avpipetteres før forsendelse/ analysering</td> </tr> <tr> <td width="40%"><strong>Referanseområde/ terapeutisk område</strong></td> <td width="60%"> <p>30-200 nmol/L</p> </td> </tr> <tr> <td width="40%"><strong>VKa (analyttisk variasjon):</strong></td> <td width="60%">&#160;</td> </tr> <tr> <td width="40%"><strong>Viktigste indikasjoner</strong></td> <td width="60%"> <p>Annengenerasjons antipsykotika</p> </td> </tr> <tr> <td width="40%"><strong>Tolkning</strong></td> <td width="60%"> <p>&#160;</p> </td> </tr> <tr> <td width="40%"><strong>Referanser</strong></td> <td width="60%"> <p>&#160;</p> </td> </tr> </tbody> </table> <p class="MsoNormal" style="margin-left: 7.1pt">&#160;</p> <o:p><span style="font-family: Arial; mso-font-kerning: 18.0pt">&#160;</span></o:p> tag:www.unn.no,2007-12-18:/laboratoriehaandbok/zuklopentixol-article39896-14289.html 2007-12-18T00:00:00+01:00 Åshild Halvorsen <p>&#160; Preparatnavn: Cisordinol</p> <table cellpadding="2" width="89%" border="1"> <tbody> <tr> <td width="40%"><strong>Laboratorium</strong></td> <td width="60%">Laboratoriemedisin, Universitetssykehuset Nord-Norge, 9038 Tromsø. Klinisk farmakologi tlf. 77626706</td> </tr> <tr> <td width="40%"><strong>Materiale</strong></td> <td width="60%"> <p><span>Serum&#160;uten gel</span></p> </td> </tr> <tr> <td width="40%"><strong>Mengde</strong></td> <td width="60%"><span>0,5 mL</span></td> </tr> <tr> <td width="40%"><strong>Prøvebehandling</strong></td> <td width="60%">Serum avpipetteres før forsendelse/ analysering</td> </tr> <tr> <td width="40%"><strong>Referanseområde/ terapeutisk område</strong></td> <td width="60%"> <p>7-30 nmol/L<br /> Ved langtidsbehandling er det ofte tilstrekkelig effekt ved konsentrasjon i nedre del av referanseområdet.</p> </td> </tr> <tr> <td width="40%"><strong>VKa (analyttisk variasjon):</strong></td> <td width="60%">&#160;</td> </tr> <tr> <td width="40%"><strong>Viktigste indikasjoner</strong></td> <td width="60%"> <p>Førstegenerasjons antipsykotika, overgang høydose - lavdose.</p> </td> </tr> <tr> <td width="40%"><strong>Tolkning</strong></td> <td width="60%"> <p>Ved langtidsbehandling er det ofte tilstrekkelig effekt ved konsentrasjon i nedre del av referanseområdet.<br /> Ekstrapamidale bivirkninger er gjerne klinisk signifikante i øvre del av referanseområdet.</p> </td> </tr> <tr> <td width="40%"><strong>Referanser</strong></td> <td width="60%"> <p>&#160;</p> </td> </tr> </tbody> </table> <p>&#160;</p> tag:www.unn.no,2007-12-18:/laboratoriehaandbok/zopiklon-article39997-14289.html 2007-12-18T00:00:00+01:00 Åshild Halvorsen <p>&#160;</p> <table cellpadding="2" width="89%" border="1"> <tbody> <tr> <td width="40%"><strong>Laboratorium</strong></td> <td width="60%">Laboratoriemedisin, Universitetssykehuset Nord-Norge, 9038 Tromsø. Fagområde farmakologi tlf. 77626706</td> </tr> <tr> <td width="40%"><strong>Materiale</strong></td> <td width="60%"> <p><span>Serum&#160;uten gel</span></p> </td> </tr> <tr> <td width="40%"><strong>Mengde</strong></td> <td width="60%"><span>0,5 mL</span></td> </tr> <tr> <td width="40%"><strong>Prøvebehandling</strong></td> <td width="60%">Serum avpipetteres før forsendelse/ analysering</td> </tr> <tr> <td width="40%"><strong>Referanseområde/ terapeutisk område</strong></td> <td width="60%"> <p>&#160;</p> </td> </tr> <tr> <td width="40%"><strong>VKa (analyttisk variasjon):</strong></td> <td width="60%">&#160;</td> </tr> <tr> <td width="40%"><strong>Viktigste indikasjoner</strong></td> <td width="60%"> <p>&#160;</p> </td> </tr> <tr> <td width="40%"><strong>Tolkning</strong></td> <td width="60%"> <p>&#160;</p> </td> </tr> <tr> <td width="40%"><strong>Referanser</strong></td> <td width="60%"> <p>&#160;</p> </td> </tr> </tbody> </table> tag:www.unn.no,2007-12-18:/laboratoriehaandbok/benzodiazepiner-urin-article41792-14289.html 2007-12-18T00:00:00+01:00 Åshild Halvorsen

Alprazolam, Diazepam, Nordiazepam, Flurazepam, Klonazepam, Okszepam, Nitrazepam, Flunitrazepam og Midazolam.

<table cellpadding="2" width="89%" border="1"> <tbody> <tr> <td width="40%"><strong>Laboratorium</strong></td> <td width="60%">Laboratoriemedisin, Universitetssykehuset Nord-Norge, 9038 Tromsø.&#160;Klinisk farmakologi tlf. 77626706</td> </tr> <tr> <td width="40%"><strong>Materiale</strong></td> <td width="60%"> <p>Urin</p> </td> </tr> <tr> <td width="40%"><strong>Mengde</strong></td> <td width="60%">1 mL</td> </tr> <tr> <td width="40%"><strong>Prøvebehandling</strong></td> <td width="60%">&#160;</td> </tr> <tr> <td width="40%"><strong>Referanseområde</strong></td> <td width="60%"> <p>&#160;</p> </td> </tr> <tr> <td width="40%"><strong>VKa (analyttisk variasjon):</strong></td> <td width="60%">&#160;</td> </tr> <tr> <td width="40%"><strong>Viktigste indikasjoner</strong></td> <td width="60%">&#160;</td> </tr> <tr> <td width="40%"><strong>Farmakologiske data</strong></td> <td width="60%">&#160;</td> </tr> <tr> <td width="40%"><strong>Referanser</strong></td> <td width="60%"> <p>&#160;</p> </td> </tr> </tbody> </table> <p>&#160;</p> tag:www.unn.no,2007-12-18:/laboratoriehaandbok/kokain-urin-article41795-14289.html 2007-12-18T00:00:00+01:00 Åshild Halvorsen

Benzylecgonin.

<p>&#160;</p> <table cellpadding="2" width="89%" border="1"> <tbody> <tr> <td width="40%"><strong>Laboratorium</strong></td> <td width="60%">Laboratoriemedisin, Universitetssykehuset Nord-Norge, 9038 Tromsø.&#160;Klinisk farmakologi tlf. 77626706</td> </tr> <tr> <td width="40%"><strong>Materiale</strong></td> <td width="60%"> <p><span>Urin</span></p> </td> </tr> <tr> <td width="40%"><strong>Mengde</strong></td> <td width="60%"><span>1&#160;mL</span></td> </tr> <tr> <td width="40%"><strong>Prøvebehandling</strong></td> <td width="60%">&#160;</td> </tr> <tr> <td width="40%"><strong>Referanseområde/ terapeutisk område</strong></td> <td width="60%"> <p>&#160;</p> </td> </tr> <tr> <td width="40%"><strong>VKa (analyttisk variasjon):</strong></td> <td width="60%">&#160;</td> </tr> <tr> <td width="40%"><strong>Viktigste indikasjoner</strong></td> <td width="60%"> <p>&#160;</p> </td> </tr> <tr> <td width="40%"><strong>Tolkning</strong></td> <td width="60%"> <p>&#160;</p> </td> </tr> <tr> <td width="40%"><strong>Referanser</strong></td> <td width="60%"> <p>&#160;</p> </td> </tr> </tbody> </table> <p>&#160;</p> tag:www.unn.no,2007-12-18:/laboratoriehaandbok/buprenorfin-urin-article41796-14289.html 2007-12-18T00:00:00+01:00 Åshild Halvorsen <p>&#160;</p> <table cellpadding="2" width="89%" border="1"> <tbody> <tr> <td width="40%"><strong>Laboratorium</strong></td> <td width="60%">Laboratoriemedisin, Universitetssykehuset Nord-Norge, 9038 Tromsø.Klinisk farmakologi tlf. 77626706</td> </tr> <tr> <td width="40%"><strong>Materiale</strong></td> <td width="60%"> <p><span>Urin</span></p> </td> </tr> <tr> <td width="40%"><strong>Mengde</strong></td> <td width="60%"><span>1&#160;mL</span></td> </tr> <tr> <td width="40%"><strong>Prøvebehandling</strong></td> <td width="60%">&#160;</td> </tr> <tr> <td width="40%"><strong>Referanseområde/ terapeutisk område</strong></td> <td width="60%"> <p>&#160;</p> </td> </tr> <tr> <td width="40%"><strong>VKa (analyttisk variasjon):</strong></td> <td width="60%">&#160;</td> </tr> <tr> <td width="40%"><strong>Viktigste indikasjoner</strong></td> <td width="60%"> <p>&#160;</p> </td> </tr> <tr> <td width="40%"><strong>Tolkning</strong></td> <td width="60%"> <p>&#160;</p> </td> </tr> <tr> <td width="40%"><strong>Referanser</strong></td> <td width="60%"> <p>&#160;</p> </td> </tr> </tbody> </table> <p>&#160;</p> tag:www.unn.no,2007-12-18:/laboratoriehaandbok/metadon-eddp-urin-article41797-14289.html 2007-12-18T00:00:00+01:00 Åshild Halvorsen <p>&#160;</p> <table cellpadding="2" width="89%" border="1"> <tbody> <tr> <td width="40%"><strong>Laboratorium</strong></td> <td width="60%">Laboratoriemedisin, Universitetssykehuset Nord-Norge, 9038 Tromsø. Klinisk farmakologi tlf. 77626706</td> </tr> <tr> <td width="40%"><strong>Materiale</strong></td> <td width="60%"> <p><span>Urin</span></p> </td> </tr> <tr> <td width="40%"><strong>Mengde</strong></td> <td width="60%"><span>1&#160;mL</span></td> </tr> <tr> <td width="40%"><strong>Prøvebehandling</strong></td> <td width="60%">&#160;</td> </tr> <tr> <td width="40%"><strong>Referanseområde/ terapeutisk område</strong></td> <td width="60%"> <p>&#160;</p> </td> </tr> <tr> <td width="40%"><strong>VKa (analyttisk variasjon):</strong></td> <td width="60%">&#160;</td> </tr> <tr> <td width="40%"><strong>Viktigste indikasjoner</strong></td> <td width="60%"> <p>&#160;</p> </td> </tr> <tr> <td width="40%"><strong>Tolkning</strong></td> <td width="60%"> <p>&#160;</p> </td> </tr> <tr> <td width="40%"><strong>Referanser</strong></td> <td width="60%"> <p>&#160;</p> </td> </tr> </tbody> </table> tag:www.unn.no,2007-12-18:/laboratoriehaandbok/ghb-urin-article41798-14289.html 2007-12-18T00:00:00+01:00 Åshild Halvorsen <p>&#160;</p> <table cellpadding="2" width="89%" border="1"> <tbody> <tr> <td width="40%"><strong>Laboratorium</strong></td> <td width="60%">Laboratoriemedisin, Universitetssykehuset Nord-Norge, 9038 Tromsø. Klinisk farmakologi tlf. 77626706</td> </tr> <tr> <td width="40%"><strong>Materiale</strong></td> <td width="60%"> <p><span>Urin</span></p> </td> </tr> <tr> <td width="40%"><strong>Mengde</strong></td> <td width="60%"><span>1&#160;mL</span></td> </tr> <tr> <td width="40%"><strong>Prøvebehandling</strong></td> <td width="60%">&#160;</td> </tr> <tr> <td width="40%"><strong>Referanseområde/ terapeutisk område</strong></td> <td width="60%"> <p>&#160;</p> </td> </tr> <tr> <td width="40%"><strong>VKa (analyttisk variasjon):</strong></td> <td width="60%">&#160;</td> </tr> <tr> <td width="40%"><strong>Viktigste indikasjoner</strong></td> <td width="60%"> <p>&#160;</p> </td> </tr> <tr> <td width="40%"><strong>Tolkning</strong></td> <td width="60%"> <p>&#160;</p> </td> </tr> <tr> <td width="40%"><strong>Referanser</strong></td> <td width="60%"> <p>&#160;</p> </td> </tr> </tbody> </table> <p>&#160;</p> tag:www.unn.no,2007-12-18:/laboratoriehaandbok/lsd-urin-article41799-14289.html 2007-12-18T00:00:00+01:00 Åshild Halvorsen <p>&#160;</p> <table cellpadding="2" width="89%" border="1"> <tbody> <tr> <td width="40%"><strong>Laboratorium</strong></td> <td width="60%">Laboratoriemedisin, Universitetssykehuset Nord-Norge, 9038 Tromsø.&#160;Klinisk farmakologi tlf. 77626706</td> </tr> <tr> <td width="40%"><strong>Materiale</strong></td> <td width="60%"> <p><span>Urin</span></p> </td> </tr> <tr> <td width="40%"><strong>Mengde</strong></td> <td width="60%"><span>1&#160;mL</span></td> </tr> <tr> <td width="40%"><strong>Prøvebehandling</strong></td> <td width="60%">&#160;</td> </tr> <tr> <td width="40%"><strong>Referanseområde/ terapeutisk område</strong></td> <td width="60%"> <p>&#160;</p> </td> </tr> <tr> <td width="40%"><strong>VKa (analyttisk variasjon):</strong></td> <td width="60%">&#160;</td> </tr> <tr> <td width="40%"><strong>Viktigste indikasjoner</strong></td> <td width="60%"> <p>&#160;</p> </td> </tr> <tr> <td width="40%"><strong>Tolkning</strong></td> <td width="60%"> <p>&#160;</p> </td> </tr> <tr> <td width="40%"><strong>Referanser</strong></td> <td width="60%"> <p>&#160;</p> </td> </tr> </tbody> </table> <p>&#160;</p> tag:www.unn.no,2007-12-18:/laboratoriehaandbok/pcp-urin-article41800-14289.html 2007-12-18T00:00:00+01:00 Åshild Halvorsen

Fencyklidin

<p>&#160;</p> <table cellpadding="2" width="89%" border="1"> <tbody> <tr> <td width="40%"><strong>Laboratorium</strong></td> <td width="60%">Laboratoriemedisin, Universitetssykehuset Nord-Norge, 9038 Tromsø.&#160;Klinisk farmakologi tlf. 77626706</td> </tr> <tr> <td width="40%"><strong>Materiale</strong></td> <td width="60%"> <p><span>Urin</span></p> </td> </tr> <tr> <td width="40%"><strong>Mengde</strong></td> <td width="60%"><span>1&#160;mL</span></td> </tr> <tr> <td width="40%"><strong>Prøvebehandling</strong></td> <td width="60%">&#160;</td> </tr> <tr> <td width="40%"><strong>Referanseområde/ terapeutisk område</strong></td> <td width="60%"> <p>&#160;</p> </td> </tr> <tr> <td width="40%"><strong>VKa (analyttisk variasjon):</strong></td> <td width="60%">&#160;</td> </tr> <tr> <td width="40%"><strong>Viktigste indikasjoner</strong></td> <td width="60%"> <p>&#160;</p> </td> </tr> <tr> <td width="40%"><strong>Tolkning</strong></td> <td width="60%"> <p>&#160;</p> </td> </tr> <tr> <td width="40%"><strong>Referanser</strong></td> <td width="60%"> <p>&#160;</p> </td> </tr> </tbody> </table> <p>&#160;</p> tag:www.unn.no,2007-12-18:/laboratoriehaandbok/zopiklon-urin-article41801-14289.html 2007-12-18T00:00:00+01:00 Åshild Halvorsen <p>&#160;</p> <table cellpadding="2" width="89%" border="1"> <tbody> <tr> <td width="40%"><strong>Laboratorium</strong></td> <td width="60%">Laboratoriemedisin, Universitetssykehuset Nord-Norge, 9038 Tromsø.&#160;Klinisk farmakologi tlf. 77626706</td> </tr> <tr> <td width="40%"><strong>Materiale</strong></td> <td width="60%"> <p><span>Urin</span></p> </td> </tr> <tr> <td width="40%"><strong>Mengde</strong></td> <td width="60%"><span>1&#160;mL</span></td> </tr> <tr> <td width="40%"><strong>Prøvebehandling</strong></td> <td width="60%">&#160;</td> </tr> <tr> <td width="40%"><strong>Referanseområde/ terapeutisk område</strong></td> <td width="60%"> <p>&#160;</p> </td> </tr> <tr> <td width="40%"><strong>VKa (analyttisk variasjon):</strong></td> <td width="60%">&#160;</td> </tr> <tr> <td width="40%"><strong>Viktigste indikasjoner</strong></td> <td width="60%"> <p>&#160;</p> </td> </tr> <tr> <td width="40%"><strong>Tolkning</strong></td> <td width="60%"> <p>&#160;</p> </td> </tr> <tr> <td width="40%"><strong>Referanser</strong></td> <td width="60%"> <p>&#160;</p> </td> </tr> </tbody> </table> tag:www.unn.no,2007-12-14:/laboratoriehaandbok/redusert-haloperidol-article39884-14289.html 2007-12-14T00:00:00+01:00 Åshild Halvorsen <div class="ctsitebase-articledisplay-body" id="cpart-editbody-14763-full" style="display: none"> <table cellpadding="2" width="89%" border="1"> <tbody> <tr> <td width="40%"><strong>Laboratorium</strong></td> <td width="60%">Laboratoriemedisin, Universitetssykehuset Nord-Norge, 9038 Tromsø. Fagområde farmakologi tlf. 77626706</td> </tr> <tr> <td width="40%"><strong>Materiale</strong></td> <td width="60%"> <p><span>Serum&#160;uten gel</span></p> </td> </tr> <tr> <td width="40%"><strong>Mengde</strong></td> <td width="60%"><span>0,5 mL</span></td> </tr> <tr> <td width="40%"><strong>Prøvebehandling</strong></td> <td width="60%">Serum avpipetteres før forsendelse/ analysering</td> </tr> <tr> <td width="40%"><strong>Referanseområde/ terapeutisk område</strong></td> <td width="60%"> <p>&#160;</p> </td> </tr> <tr> <td width="40%"><strong>VKa (analyttisk variasjon):</strong></td> <td width="60%">&#160;</td> </tr> <tr> <td width="40%"><strong>Viktigste indikasjoner</strong></td> <td width="60%"> <p>&#160;</p> </td> </tr> <tr> <td width="40%"><strong>Tolkning</strong></td> <td width="60%"> <p>&#160;</p> </td> </tr> <tr> <td width="40%"><strong>Referanser</strong></td> <td width="60%"> <p>&#160;</p> </td> </tr> </tbody> </table> &#160;</div> <p>&#160;<br /> <br /> &#160;</p> <p>&#160;</p> tag:www.unn.no,2007-12-14:/laboratoriehaandbok/olanzapin-article39890-14289.html 2007-12-14T00:00:00+01:00 Åshild Halvorsen <p>&#160;&#160;<span style="display: none; font-size: 16pt; font-family: Arial; mso-hide: all">&#160;<span style="font-size: small">Preparatnavn: Olanzapin, Zyprexa</span></span></p> <table cellpadding="2" width="89%" border="1"> <tbody> <tr> <td width="40%"><strong>Laboratorium</strong></td> <td width="60%">Laboratoriemedisin, Universitetssykehuset Nord-Norge, 9038 Tromsø.&#160;Klinisk farmakologi tlf. 77626706</td> </tr> <tr> <td width="40%"><strong>Materiale</strong></td> <td width="60%"> <p><span>Serum&#160;uten gel</span></p> </td> </tr> <tr> <td width="40%"><strong>Mengde</strong></td> <td width="60%"><span>0,5 mL</span></td> </tr> <tr> <td width="40%"><strong>Prøvebehandling</strong></td> <td width="60%">Serum avpipetteres før forsendelse/ analysering</td> </tr> <tr> <td width="40%"><strong>Referanseområde/ terapeutisk område</strong></td> <td width="60%"> <p>25-150 nmol/L</p> </td> </tr> <tr> <td width="40%"><strong>VKa (analyttisk variasjon):</strong></td> <td width="60%">&#160;</td> </tr> <tr> <td width="40%"><strong>Viktigste indikasjoner</strong></td> <td width="60%"> <p>Annengenerasjons antipsykotika</p> </td> </tr> <tr> <td width="40%"><strong>Tolkning</strong></td> <td width="60%"> <p>&#160;</p> </td> </tr> <tr> <td width="40%"><strong>Referanser</strong></td> <td width="60%"> <p>&#160;</p> </td> </tr> </tbody> </table> <p>&#160;</p> <o:p></o:p> <p>&#160;</p> tag:www.unn.no,2007-12-14:/laboratoriehaandbok/perfenazin-article39891-14289.html 2007-12-14T00:00:00+01:00 Åshild Halvorsen <p>&#160; Preparatnavn: Trilafon</p> <table cellpadding="2" width="89%" border="1"> <tbody> <tr> <td width="40%"><strong>Laboratorium</strong></td> <td width="60%">Laboratoriemedisin, Universitetssykehuset Nord-Norge, 9038 Tromsø.&#160;Klinisk farmakologi tlf. 77626706</td> </tr> <tr> <td width="40%"><strong>Materiale</strong></td> <td width="60%"> <p><span>Serum&#160;uten gel</span></p> </td> </tr> <tr> <td width="40%"><strong>Mengde</strong></td> <td width="60%"><span>0,5 mL</span></td> </tr> <tr> <td width="40%"><strong>Prøvebehandling</strong></td> <td width="60%">Serum avpipetteres før forsendelse/ analysering</td> </tr> <tr> <td width="40%"><strong>Referanseområde/ terapeutisk område</strong></td> <td width="60%"> <p>2,0-6,0 nmol/L</p> </td> </tr> <tr> <td width="40%"><strong>VKa (analyttisk variasjon):</strong></td> <td width="60%">&#160;</td> </tr> <tr> <td width="40%"><strong>Viktigste indikasjoner</strong></td> <td width="60%"> <p>Førstegenerasjons antipsykotika, overgang høydose - lavdose.</p> </td> </tr> <tr> <td width="40%"><strong>Tolkning</strong></td> <td width="60%"> <p>&#160;</p> </td> </tr> <tr> <td width="40%"><strong>Referanser</strong></td> <td width="60%"> <p>&#160;</p> </td> </tr> </tbody> </table> <p class="MsoNormal" style="margin-left: 7.1pt">&#160;</p> tag:www.unn.no,2007-12-14:/laboratoriehaandbok/quetiapin-article39892-14289.html 2007-12-14T00:00:00+01:00 Åshild Halvorsen <p><span style="display: none; font-size: 16pt; font-family: Arial; mso-hide: all">&#160;<span style="font-size: small">Preparatnavn: Seroquel</span></span></p> <table cellpadding="2" width="89%" border="1"> <tbody> <tr> <td width="40%"><strong>Laboratorium</strong></td> <td width="60%">Laboratoriemedisin, Universitetssykehuset Nord-Norge, 9038 Tromsø. Fagområde farmakologi tlf. 77626706</td> </tr> <tr> <td width="40%"><strong>Materiale</strong></td> <td width="60%"> <p><span>Serum&#160;uten gel</span></p> </td> </tr> <tr> <td width="40%"><strong>Mengde</strong></td> <td width="60%"><span>0,5 mL</span></td> </tr> <tr> <td width="40%"><strong>Prøvebehandling</strong></td> <td width="60%">Serum avpipetteres før forsendelse/ analysering</td> </tr> <tr> <td width="40%"><strong>Referanseområde/ terapeutisk område</strong></td> <td width="60%"> <p>100-800 nmol/L</p> </td> </tr> <tr> <td width="40%"><strong>VKa (analyttisk variasjon):</strong></td> <td width="60%">&#160;</td> </tr> <tr> <td width="40%"><strong>Viktigste indikasjoner</strong></td> <td width="60%"> <p>Annengenerasjons antipsykotika</p> </td> </tr> <tr> <td width="40%"><strong>Tolkning</strong></td> <td width="60%"> <p>&#160;</p> </td> </tr> <tr> <td width="40%"><strong>Referanser</strong></td> <td width="60%"> <p>&#160;</p> </td> </tr> </tbody> </table> <p>&#160;</p> tag:www.unn.no,2007-12-14:/laboratoriehaandbok/risperidon-article39893-14289.html 2007-12-14T00:00:00+01:00 Åshild Halvorsen <p>&#160; Preparatnavn: Risperdal, Risperdon</p> <table cellpadding="2" width="89%" border="1"> <tbody> <tr> <td width="40%"><strong>Laboratorium</strong></td> <td width="60%">Laboratoriemedisin, Universitetssykehuset Nord-Norge, 9038 Tromsø.&#160;Klinisk farmakologi tlf. 77626706</td> </tr> <tr> <td width="40%"><strong>Materiale</strong></td> <td width="60%"> <p><span>Serum&#160;uten gel</span></p> </td> </tr> <tr> <td width="40%"><strong>Mengde</strong></td> <td width="60%"><span>0,5 mL</span></td> </tr> <tr> <td width="40%"><strong>Prøvebehandling</strong></td> <td width="60%">Serum avpipetteres før forsendelse/ analysering</td> </tr> <tr> <td width="40%"><strong>Referanseområde/ terapeutisk område</strong></td> <td width="60%"> <p>50-150&#160;nmol/L</p> </td> </tr> <tr> <td width="40%"><strong>VKa (analyttisk variasjon):</strong></td> <td width="60%">&#160;</td> </tr> <tr> <td width="40%"><strong>Viktigste indikasjoner</strong></td> <td width="60%"> <p>Annengenerasjons antipsykotika</p> </td> </tr> <tr> <td width="40%"><strong>Tolkning</strong></td> <td width="60%"> <p>&#160;</p> </td> </tr> <tr> <td width="40%"><strong>Referanser</strong></td> <td width="60%"> <p>&#160;</p> </td> </tr> </tbody> </table> <p>&#160;</p> tag:www.unn.no,2007-12-14:/laboratoriehaandbok/okskarbazepin-article39965-14289.html 2007-12-14T00:00:00+01:00 Åshild Halvorsen <p>&#160;</p> <table cellpadding="2" width="89%" border="1"> <tbody> <tr> <td width="40%"><strong>Laboratorium</strong></td> <td width="60%">Laboratoriemedisin, Universitetssykehuset Nord-Norge, 9038 Tromsø. Fagområde farmakologi tlf. 77626706</td> </tr> <tr> <td width="40%"><strong>Materiale</strong></td> <td width="60%"> <p><span>Serum&#160;uten gel</span></p> </td> </tr> <tr> <td width="40%"><strong>Mengde</strong></td> <td width="60%"><span>0,5 mL</span></td> </tr> <tr> <td width="40%"><strong>Prøvebehandling</strong></td> <td width="60%">Serum avpipetteres før forsendelse/ analysering</td> </tr> <tr> <td width="40%"><strong>Referanseområde/ terapeutisk område</strong></td> <td width="60%"> <p>&#160;</p> </td> </tr> <tr> <td width="40%"><strong>VKa (analyttisk variasjon):</strong></td> <td width="60%">&#160;</td> </tr> <tr> <td width="40%"><strong>Viktigste indikasjoner</strong></td> <td width="60%"> <p>&#160;</p> </td> </tr> <tr> <td width="40%"><strong>Tolkning</strong></td> <td width="60%"> <p>&#160;</p> </td> </tr> <tr> <td width="40%"><strong>Referanser</strong></td> <td width="60%"> <p>&#160;</p> </td> </tr> </tbody> </table> tag:www.unn.no,2007-12-14:/laboratoriehaandbok/pregabalin-i-serum-article39967-14289.html 2007-12-14T00:00:00+01:00 Åshild Halvorsen <p> &nbsp;</p> <table border="1" cellpadding="0" cellspacing="0"> <tbody> <tr> <td> <p> <strong>Laboratorium</strong></p> </td> <td> <p> <strong>Fagområdet Klinisk farmakologi, </strong><br /> <strong>Laboratoriemedisin, </strong><br /> <strong>Universitetssykehuset Nord-Norge, 9038 Tromsø.</strong></p> <p> <strong>Tlf. 776 26718 (prøvesvar)&nbsp;</strong><br /> <strong>Tlf. 776 26706 (legemiddel- og rusmiddelanalyser)</strong></p> </td> </tr> <tr> <td> <p> <strong>Prøvemateriale</strong></p> </td> <td> <p> <strong>Serum</strong></p> </td> </tr> <tr> <td> <p> <strong>Mengde</strong></p> </td> <td> <p> <strong>0,5 mL </strong></p> </td> </tr> <tr> <td> <p> <strong>Prøvetakingsrutiner</strong></p> </td> <td> <p> <strong><u>Pasientforberedelse </u></strong><br /> <strong>Prøven tas ved bunnkonsentrasjon, like før inntak av neste dose. </strong><strong>Prøven tas ved stabil likevekt, </strong><strong>minst 2 dager etter oppstart eller doseendring.</strong></p> <p> <strong><u>Prøvetaking </u></strong><br /> <strong>Bruk glass uten gel. Serum avpipetteres og oppbevares kjølig før forsendelse. </strong></p> </td> </tr> <tr> <td> <p> <strong>Analysedag(er)</strong></p> </td> <td> <p> <strong>Mandag </strong></p> </td> </tr> <tr> <td> <p> <strong>Referanseområde</strong></p> </td> <td> <p> <strong>5-30 &micro;mol/L.</strong><br /> <strong>Gjelder epilepsi.</strong></p> </td> </tr> <tr> <td> <p> <strong>VKa (analytisk variasjon)</strong></p> </td> <td> <p> &nbsp;</p> </td> </tr> <tr> <td> <p> <strong>Viktigste indikasjoner</strong></p> </td> <td> <p> <strong>Terapikontroll, vurdering av etterlevelse, bivirkninger og interaksjoner, samt intoksikasjonsutredning.</strong></p> </td> </tr> <tr> <td> <p> <strong>Farmakologiske data</strong></p> </td> <td> <p> <strong>Molekylvekt: 159. </strong><strong>Biotilgjengelighet: &gt;90%. </strong><strong>T</strong><strong>_max</strong><strong>: ca 1 t. T</strong><strong>_1/2</strong><strong>: ca 6 t. Ingen binding til plasmaproteiner.&nbsp; Metabolisme: ubetydelig (&lt;2%)</strong><strong>.</strong><strong>Utskilles uforandret i urin. &nbsp;</strong></p> </td> </tr> <tr> <td> <p> <strong>Tolkning</strong></p> </td> <td> <p> <strong>Moderat akutt toksisitet. Symptomer og tegn på overdosering kan være somnolens, forvirring, agitasjon og rastløshet.</strong></p> </td> </tr> </tbody> </table> tag:www.unn.no,2007-12-14:/laboratoriehaandbok/topiramat-i-serum-article39968-14289.html 2007-12-14T00:00:00+01:00 Åshild Halvorsen <p> &nbsp;</p> <table border="1" cellpadding="0" cellspacing="0"> <tbody> <tr> <td> <p> <strong>Laboratorium</strong></p> </td> <td> <p> <strong>Fagområdet Klinisk farmakologi, </strong><br /> <strong>Laboratoriemedisin, </strong><br /> <strong>Universitetssykehuset Nord-Norge, 9038 Tromsø.</strong></p> <p> <strong>Tlf. 776 26718</strong><strong>(prøvesvar)&nbsp;</strong><br /> <strong>Tlf. 776 26706</strong><strong>(legemiddel- og rusmiddelanalyser)</strong></p> </td> </tr> <tr> <td> <p> <strong>Prøvemateriale</strong></p> </td> <td> <p> <strong>Serum</strong></p> </td> </tr> <tr> <td> <p> <strong>Mengde</strong></p> </td> <td> <p> <strong>0,5 mL </strong></p> </td> </tr> <tr> <td> <p> <strong>Prøvetakingsrutiner</strong></p> </td> <td> <p> <strong><u>Pasientforberedelse </u></strong><br /> <strong>Prøven tas ved bunnkonsentrasjon, like før inntak av neste dose, dvs ca 12 timer etter siste dose ved dosering x2 per dag og ca 24 timer etter siste dose ved dosering x1 per dag. </strong><strong>Prøven tas ved stabil likevekt, </strong><strong>minst 4 dager etter oppstart eller doseendring.</strong></p> <p> <strong><u>Prøvetaking </u></strong><br /> <strong>Bruk glass uten gel. Serum avpipetteres og oppbevares kjølig før forsendelse. </strong></p> </td> </tr> <tr> <td> <p> <strong>Analysedag</strong><strong>(er)</strong></p> </td> <td> <p> <strong>Mandag</strong></p> </td> </tr> <tr> <td> <p> <strong>Referanseområde</strong></p> </td> <td> <p> <strong>15-60 &micro;mol/L</strong></p> </td> </tr> <tr> <td> <p> <strong>VKa</strong><strong>(analytisk variasjon)</strong></p> </td> <td> <p> &nbsp;</p> </td> </tr> <tr> <td> <p> <strong>Viktigste indikasjoner</strong></p> </td> <td> <p> <strong>Terapikontroll, vurdering av etterlevelse, bivirkninger og interaksjoner, samt intoksikasjonsutredning.</strong></p> </td> </tr> <tr> <td> <p> <strong>Farmakologiske data</strong></p> </td> <td> <p> <strong>Molekylvekt: </strong><strong>339</strong><strong>. </strong><strong>Biotilgjengelighet</strong><strong>: ca 80%. </strong><strong>T</strong><strong>_max</strong><strong>: 2-3 t. T</strong><strong>_1/2</strong><strong>: ca 21 t. Proteinbinding: ca 15%. </strong><strong>Metaboliseres</strong><strong>i lever </strong><strong>(ca 20%).</strong><strong>Utskilles renalt (ca 80% utskilles uforandret). </strong></p> </td> </tr> <tr> <td> <p> <strong>Tolkning</strong></p> </td> <td> <p> <strong>Moderat akutt toksisitet. Symptomer og tegn på overdosering kan være synsforstyrrelser, talevansker, nedsatt bevissthet, kramper og alvorlig metabolsk acidose. </strong></p> </td> </tr> </tbody> </table> tag:www.unn.no,2007-12-14:/laboratoriehaandbok/ppa-article39986-14289.html 2007-12-14T00:00:00+01:00 Åshild Halvorsen <p>&#160;</p> <table cellpadding="2" width="89%" border="1"> <tbody> <tr> <td width="40%"><strong>Laboratorium</strong></td> <td width="60%">Laboratoriemedisin, Universitetssykehuset Nord-Norge, 9038 Tromsø.&#160;Klinisk farmakologi tlf. 77626706</td> </tr> <tr> <td width="40%"><strong>Materiale</strong></td> <td width="60%"> <p><span>Serum&#160;uten gel</span></p> </td> </tr> <tr> <td width="40%"><strong>Mengde</strong></td> <td width="60%"><span>0,5 mL</span></td> </tr> <tr> <td width="40%"><strong>Prøvebehandling</strong></td> <td width="60%">Serum avpipetteres før forsendelse/ analysering</td> </tr> <tr> <td width="40%"><strong>Referanseområde/ terapeutisk område</strong></td> <td width="60%"> <p>&#160;</p> </td> </tr> <tr> <td width="40%"><strong>VKa (analyttisk variasjon):</strong></td> <td width="60%">&#160;</td> </tr> <tr> <td width="40%"><strong>Viktigste indikasjoner</strong></td> <td width="60%"> <p>&#160;</p> </td> </tr> <tr> <td width="40%"><strong>Tolkning</strong></td> <td width="60%"> <p>&#160;</p> </td> </tr> <tr> <td width="40%"><strong>Referanser</strong></td> <td width="60%"> <p>&#160;</p> </td> </tr> </tbody> </table> <p>&#160;</p> tag:www.unn.no,2007-12-14:/laboratoriehaandbok/nordiazepam-article39989-14289.html 2007-12-14T00:00:00+01:00 Åshild Halvorsen <p>&#160;</p> <table cellpadding="2" width="89%" border="1"> <tbody> <tr> <td width="40%"><strong>Laboratorium</strong></td> <td width="60%">Laboratoriemedisin, Universitetssykehuset Nord-Norge, 9038 Tromsø. Klinisk farmakologi tlf. 77626706</td> </tr> <tr> <td width="40%"><strong>Materiale</strong></td> <td width="60%"> <p><span>Serum&#160;uten gel</span></p> </td> </tr> <tr> <td width="40%"><strong>Mengde</strong></td> <td width="60%"><span>0,5 mL</span></td> </tr> <tr> <td width="40%"><strong>Prøvebehandling</strong></td> <td width="60%">Serum avpipetteres før forsendelse/ analysering</td> </tr> <tr> <td width="40%"><strong>Referanseområde/ terapeutisk område</strong></td> <td width="60%"> <p>&#160;</p> </td> </tr> <tr> <td width="40%"><strong>VKa (analyttisk variasjon):</strong></td> <td width="60%">&#160;</td> </tr> <tr> <td width="40%"><strong>Viktigste indikasjoner</strong></td> <td width="60%"> <p>&#160;</p> </td> </tr> <tr> <td width="40%"><strong>Tolkning</strong></td> <td width="60%"> <p>&#160;</p> </td> </tr> <tr> <td width="40%"><strong>Referanser</strong></td> <td width="60%"> <p>&#160;</p> </td> </tr> </tbody> </table> <p>&#160;</p> tag:www.unn.no,2007-12-14:/laboratoriehaandbok/oksazepam-article39992-14289.html 2007-12-14T00:00:00+01:00 Åshild Halvorsen <p>&#160;</p> <table cellpadding="2" width="89%" border="1"> <tbody> <tr> <td width="40%"><strong>Laboratorium</strong></td> <td width="60%">Laboratoriemedisin, Universitetssykehuset Nord-Norge, 9038 Tromsø. Klinisk farmakologi tlf. 77626706</td> </tr> <tr> <td width="40%"><strong>Materiale</strong></td> <td width="60%"> <p><span>Serum&#160;uten gel</span></p> </td> </tr> <tr> <td width="40%"><strong>Mengde</strong></td> <td width="60%"><span>0,5 mL</span></td> </tr> <tr> <td width="40%"><strong>Prøvebehandling</strong></td> <td width="60%">Serum avpipetteres før forsendelse/ analysering</td> </tr> <tr> <td width="40%"><strong>Referanseområde/ terapeutisk område</strong></td> <td width="60%"> <p>&#160;</p> </td> </tr> <tr> <td width="40%"><strong>VKa (analyttisk variasjon):</strong></td> <td width="60%">&#160;</td> </tr> <tr> <td width="40%"><strong>Viktigste indikasjoner</strong></td> <td width="60%"> <p>&#160;</p> </td> </tr> <tr> <td width="40%"><strong>Tolkning</strong></td> <td width="60%"> <p>&#160;</p> </td> </tr> <tr> <td width="40%"><strong>Referanser</strong></td> <td width="60%"> <p>&#160;</p> </td> </tr> </tbody> </table> <p>&#160;</p> tag:www.unn.no,2007-12-14:/laboratoriehaandbok/nitrazepam-article39993-14289.html 2007-12-14T00:00:00+01:00 Åshild Halvorsen <p>&#160;</p> <table cellpadding="2" width="89%" border="1"> <tbody> <tr> <td width="40%"><strong>Laboratorium</strong></td> <td width="60%">Laboratoriemedisin, Universitetssykehuset Nord-Norge, 9038 Tromsø.&#160;Klinisk farmakologi tlf. 77626706</td> </tr> <tr> <td width="40%"><strong>Materiale</strong></td> <td width="60%"> <p><span>Serum&#160;uten gel</span></p> </td> </tr> <tr> <td width="40%"><strong>Mengde</strong></td> <td width="60%"><span>0,5 mL</span></td> </tr> <tr> <td width="40%"><strong>Prøvebehandling</strong></td> <td width="60%">Serum avpipetteres før forsendelse/ analysering</td> </tr> <tr> <td width="40%"><strong>Referanseområde/ terapeutisk område</strong></td> <td width="60%"> <p>&#160;</p> </td> </tr> <tr> <td width="40%"><strong>VKa (analyttisk variasjon):</strong></td> <td width="60%">&#160;</td> </tr> <tr> <td width="40%"><strong>Viktigste indikasjoner</strong></td> <td width="60%"> <p>&#160;</p> </td> </tr> <tr> <td width="40%"><strong>Tolkning</strong></td> <td width="60%"> <p>&#160;</p> </td> </tr> <tr> <td width="40%"><strong>Referanser</strong></td> <td width="60%"> <p>&#160;</p> </td> </tr> </tbody> </table> <p>&#160;</p> tag:www.unn.no,2007-12-14:/laboratoriehaandbok/thc-article40019-14289.html 2007-12-14T00:00:00+01:00 Åshild Halvorsen <p>&#160;</p> <table cellpadding="2" width="89%" border="1"> <tbody> <tr> <td width="40%"><strong>Laboratorium</strong></td> <td width="60%">Laboratoriemedisin, Universitetssykehuset Nord-Norge, 9038 Tromsø. Fagområde farmakologi tlf. 77626706</td> </tr> <tr> <td width="40%"><strong>Materiale</strong></td> <td width="60%"> <p><span>Serum&#160;uten gel</span></p> </td> </tr> <tr> <td width="40%"><strong>Mengde</strong></td> <td width="60%"><span>0,5 mL</span></td> </tr> <tr> <td width="40%"><strong>Prøvebehandling</strong></td> <td width="60%">Serum avpipetteres før forsendelse/ analysering</td> </tr> <tr> <td width="40%"><strong>Referanseområde/ terapeutisk område</strong></td> <td width="60%"> <p>&#160;</p> </td> </tr> <tr> <td width="40%"><strong>VKa (analyttisk variasjon):</strong></td> <td width="60%">&#160;</td> </tr> <tr> <td width="40%"><strong>Viktigste indikasjoner</strong></td> <td width="60%"> <p>&#160;</p> </td> </tr> <tr> <td width="40%"><strong>Tolkning</strong></td> <td width="60%"> <p>&#160;</p> </td> </tr> <tr> <td width="40%"><strong>Referanser</strong></td> <td width="60%"> <p>&#160;</p> </td> </tr> </tbody> </table> tag:www.unn.no,2007-12-14:/laboratoriehaandbok/thc-oh-article40020-14289.html 2007-12-14T00:00:00+01:00 Åshild Halvorsen <p>&#160;</p> <table cellpadding="2" width="89%" border="1"> <tbody> <tr> <td width="40%"><strong>Laboratorium</strong></td> <td width="60%">Laboratoriemedisin, Universitetssykehuset Nord-Norge, 9038 Tromsø. Fagområde farmakologi tlf. 77626706</td> </tr> <tr> <td width="40%"><strong>Materiale</strong></td> <td width="60%"> <p><span>Serum&#160;uten gel</span></p> </td> </tr> <tr> <td width="40%"><strong>Mengde</strong></td> <td width="60%"><span>0,5 mL</span></td> </tr> <tr> <td width="40%"><strong>Prøvebehandling</strong></td> <td width="60%">Serum avpipetteres før forsendelse/ analysering</td> </tr> <tr> <td width="40%"><strong>Referanseområde/ terapeutisk område</strong></td> <td width="60%"> <p>&#160;</p> </td> </tr> <tr> <td width="40%"><strong>VKa (analyttisk variasjon):</strong></td> <td width="60%">&#160;</td> </tr> <tr> <td width="40%"><strong>Viktigste indikasjoner</strong></td> <td width="60%"> <p>&#160;</p> </td> </tr> <tr> <td width="40%"><strong>Tolkning</strong></td> <td width="60%"> <p>&#160;</p> </td> </tr> <tr> <td width="40%"><strong>Referanser</strong></td> <td width="60%"> <p>&#160;</p> </td> </tr> </tbody> </table> tag:www.unn.no,2007-12-14:/laboratoriehaandbok/thc-cooh-article40021-14289.html 2007-12-14T00:00:00+01:00 Åshild Halvorsen <p>&#160;</p> <table cellpadding="2" width="89%" border="1"> <tbody> <tr> <td width="40%"><strong>Laboratorium</strong></td> <td width="60%">Laboratoriemedisin, Universitetssykehuset Nord-Norge, 9038 Tromsø. Fagområde farmakologi tlf. 77626706</td> </tr> <tr> <td width="40%"><strong>Materiale</strong></td> <td width="60%"> <p><span>Serum&#160;uten gel</span></p> </td> </tr> <tr> <td width="40%"><strong>Mengde</strong></td> <td width="60%"><span>0,5 mL</span></td> </tr> <tr> <td width="40%"><strong>Prøvebehandling</strong></td> <td width="60%">Serum avpipetteres før forsendelse/ analysering</td> </tr> <tr> <td width="40%"><strong>Referanseområde/ terapeutisk område</strong></td> <td width="60%"> <p>&#160;</p> </td> </tr> <tr> <td width="40%"><strong>VKa (analyttisk variasjon):</strong></td> <td width="60%">&#160;</td> </tr> <tr> <td width="40%"><strong>Viktigste indikasjoner</strong></td> <td width="60%"> <p>&#160;</p> </td> </tr> <tr> <td width="40%"><strong>Tolkning</strong></td> <td width="60%"> <p>&#160;</p> </td> </tr> <tr> <td width="40%"><strong>Referanser</strong></td> <td width="60%"> <p>&#160;</p> </td> </tr> </tbody> </table> tag:www.unn.no,2007-12-14:/laboratoriehaandbok/oksykodon-article40031-14289.html 2007-12-14T00:00:00+01:00 Åshild Halvorsen <p>&#160;</p> <table cellpadding="2" width="89%" border="1"> <tbody> <tr> <td width="40%"><strong>Laboratorium</strong></td> <td width="60%">Laboratoriemedisin, Universitetssykehuset Nord-Norge, 9038 Tromsø. Fagområde farmakologi tlf. 77626706</td> </tr> <tr> <td width="40%"><strong>Materiale</strong></td> <td width="60%"> <p><span>Serum&#160;uten gel</span></p> </td> </tr> <tr> <td width="40%"><strong>Mengde</strong></td> <td width="60%"><span>0,5 mL</span></td> </tr> <tr> <td width="40%"><strong>Prøvebehandling</strong></td> <td width="60%">Serum avpipetteres før forsendelse/ analysering</td> </tr> <tr> <td width="40%"><strong>Referanseområde/ terapeutisk område</strong></td> <td width="60%"> <p>&#160;</p> </td> </tr> <tr> <td width="40%"><strong>VKa (analyttisk variasjon):</strong></td> <td width="60%">&#160;</td> </tr> <tr> <td width="40%"><strong>Viktigste indikasjoner</strong></td> <td width="60%"> <p>&#160;</p> </td> </tr> <tr> <td width="40%"><strong>Tolkning</strong></td> <td width="60%"> <p>&#160;</p> </td> </tr> <tr> <td width="40%"><strong>Referanser</strong></td> <td width="60%"> <p>&#160;</p> </td> </tr> </tbody> </table> tag:www.unn.no,2007-12-14:/laboratoriehaandbok/pentazocin-article40032-14289.html 2007-12-14T00:00:00+01:00 Åshild Halvorsen <p>&#160;</p> <table cellpadding="2" width="89%" border="1"> <tbody> <tr> <td width="40%"><strong>Laboratorium</strong></td> <td width="60%">Laboratoriemedisin, Universitetssykehuset Nord-Norge, 9038 Tromsø. Fagområde farmakologi tlf. 77626706</td> </tr> <tr> <td width="40%"><strong>Materiale</strong></td> <td width="60%"> <p><span>Serum&#160;uten gel</span></p> </td> </tr> <tr> <td width="40%"><strong>Mengde</strong></td> <td width="60%"><span>0,5 mL</span></td> </tr> <tr> <td width="40%"><strong>Prøvebehandling</strong></td> <td width="60%">Serum avpipetteres før forsendelse/ analysering</td> </tr> <tr> <td width="40%"><strong>Referanseområde/ terapeutisk område</strong></td> <td width="60%"> <p>&#160;</p> </td> </tr> <tr> <td width="40%"><strong>VKa (analyttisk variasjon):</strong></td> <td width="60%">&#160;</td> </tr> <tr> <td width="40%"><strong>Viktigste indikasjoner</strong></td> <td width="60%"> <p>&#160;</p> </td> </tr> <tr> <td width="40%"><strong>Tolkning</strong></td> <td width="60%"> <p>&#160;</p> </td> </tr> <tr> <td width="40%"><strong>Referanser</strong></td> <td width="60%"> <p>&#160;</p> </td> </tr> </tbody> </table> tag:www.unn.no,2007-12-14:/laboratoriehaandbok/fensyklidin-pcp-article40036-14289.html 2007-12-14T00:00:00+01:00 Åshild Halvorsen <p>&#160;</p> <table cellpadding="2" width="89%" border="1"> <tbody> <tr> <td width="40%"><strong>Laboratorium</strong></td> <td width="60%">Laboratoriemedisin, Universitetssykehuset Nord-Norge, 9038 Tromsø. Fagområde farmakologi tlf. 77626706</td> </tr> <tr> <td width="40%"><strong>Materiale</strong></td> <td width="60%"> <p><span>Serum&#160;uten gel</span></p> </td> </tr> <tr> <td width="40%"><strong>Mengde</strong></td> <td width="60%"><span>0,5 mL</span></td> </tr> <tr> <td width="40%"><strong>Prøvebehandling</strong></td> <td width="60%">Serum avpipetteres før forsendelse/ analysering</td> </tr> <tr> <td width="40%"><strong>Referanseområde/ terapeutisk område</strong></td> <td width="60%"> <p>&#160;</p> </td> </tr> <tr> <td width="40%"><strong>VKa (analyttisk variasjon):</strong></td> <td width="60%">&#160;</td> </tr> <tr> <td width="40%"><strong>Viktigste indikasjoner</strong></td> <td width="60%"> <p>&#160;</p> </td> </tr> <tr> <td width="40%"><strong>Tolkning</strong></td> <td width="60%"> <p>&#160;</p> </td> </tr> <tr> <td width="40%"><strong>Referanser</strong></td> <td width="60%"> <p>&#160;</p> </td> </tr> </tbody> </table> tag:www.unn.no,2007-12-12:/laboratoriehaandbok/levomepromazin-article39888-14289.html 2007-12-12T00:00:00+01:00 Åshild Halvorsen <p>&#160;&#160;</p> <table cellpadding="2" width="89%" border="1"> <tbody> <tr> <td width="40%"><strong>Laboratorium</strong></td> <td width="60%">Laboratoriemedisin, Universitetssykehuset Nord-Norge, 9038 Tromsø.&#160;Klinisk&#160;farmakologi tlf. 77626706</td> </tr> <tr> <td width="40%"><strong>Materiale</strong></td> <td width="60%"> <p><span>Serum&#160;uten gel</span></p> </td> </tr> <tr> <td width="40%"><strong>Mengde</strong></td> <td width="60%"><span>0,5 mL</span></td> </tr> <tr> <td width="40%"><strong>Prøvebehandling</strong></td> <td width="60%">Serum avpipetteres før forsendelse/ analysering</td> </tr> <tr> <td width="40%"><strong>Referanseområde/ terapeutisk område</strong></td> <td width="60%"> <p>150-800 nmol/L</p> </td> </tr> <tr> <td width="40%"><strong>VKa (analyttisk variasjon):</strong></td> <td width="60%">&#160;</td> </tr> <tr> <td width="40%"><strong>Viktigste indikasjoner</strong></td> <td width="60%"> <p>Førstegenerasjons antipsykotika, høydose.</p> </td> </tr> <tr> <td width="40%"><strong>Tolkning</strong></td> <td width="60%">Uttalt sederende effekt, samt antikolonerg, antiadrenerg og antihistaminerg effekt.</td> </tr> <tr> <td width="40%"><strong>Referanser</strong></td> <td width="60%"> <p>&#160;</p> </td> </tr> </tbody> </table> <p><span style="display: none; font-size: 16pt; font-family: Arial; mso-hide: all">&#160;</span></p> <o:p></o:p> <p>&#160;</p> <table class="MsoNormalTable" style="width: 89%; mso-cellspacing: 1.5pt; mso-padding-alt: 1.5pt 1.5pt 1.5pt 1.5pt" cellpadding="0" width="89%" border="1"> <tbody> <tr style="mso-yfti-irow: 0"> <td style="padding-right: 1.5pt; padding-left: 1.5pt; padding-bottom: 1.5pt; width: 24.54%; padding-top: 1.5pt" width="24%"> <p class="MsoNormal" style="margin-left: 7.1pt"><strong><span style="font-size: 9pt; color: #454647; font-family: Arial; mso-bidi-font-size: 10.0pt">Preparatnavn</span></strong></p> <o:p></o:p></td> </tr> </tbody> </table> <p> <td style="padding-right: 1.5pt; padding-left: 1.5pt; padding-bottom: 1.5pt; width: 74.36%; padding-top: 1.5pt" width="74%">&#160;</td> </p> <table class="MsoNormalTable" style="width: 89%; mso-cellspacing: 1.5pt; mso-padding-alt: 1.5pt 1.5pt 1.5pt 1.5pt" cellpadding="0" width="89%" border="1"> <tbody> </tbody> </table> <p class="MsoNormal" style="margin-left: 7.1pt"><span style="color: #454647; font-family: Arial">Nozinan</span></p> <o:p></o:p> <p> <tr style="mso-yfti-irow: 1"> </tr> <td style="padding-right: 1.5pt; padding-left: 1.5pt; padding-bottom: 1.5pt; width: 24.54%; padding-top: 1.5pt" width="24%">&#160;</td> </p> <p class="MsoNormal" style="margin-left: 7.1pt"><strong><span style="font-size: 9pt; color: #454647; font-family: Arial; mso-bidi-font-size: 10.0pt">Prøvemateriale</span></strong></p> <o:p></o:p> <p> <td style="padding-right: 1.5pt; padding-left: 1.5pt; padding-bottom: 1.5pt; width: 74.36%; padding-top: 1.5pt" width="74%">&#160;</td> </p> <p class="MsoNormal" style="margin-left: 7.1pt"><span style="color: #454647; font-family: Arial">Serum fra glass uten gel.</span></p> <o:p></o:p> <p>&#160;</p> <p class="MsoNormal" style="margin-left: 7.1pt">&#160;</p> <o:p><span style="font-size: 9pt; color: #454647; font-family: Arial">&#160;</span></o:p> <p class="MsoNormal" style="margin-left: 7.1pt"><span style="color: #454647; font-family: Arial">Min 0,5 ml</span></p> <o:p></o:p> <p> <tr style="mso-yfti-irow: 2"> </tr> <td style="padding-right: 1.5pt; padding-left: 1.5pt; padding-bottom: 1.5pt; width: 24.54%; padding-top: 1.5pt" width="24%">&#160;</td> </p> <p class="MsoNormal" style="margin-left: 7.1pt"><strong><span style="font-size: 9pt; color: #454647; font-family: Arial; mso-bidi-font-size: 10.0pt">Prøvebehandling</span></strong></p> <o:p></o:p> <p> <td style="padding-right: 1.5pt; padding-left: 1.5pt; padding-bottom: 1.5pt; width: 74.36%; padding-top: 1.5pt" width="74%">&#160;</td> </p> <p class="MsoNormal" style="margin-left: 7.1pt"><span style="color: #454647; font-family: Arial">Prøven bør tas kort tid før neste planlagte dose, etter at stabil likevekt er etablert.</span></p> <o:p></o:p> <p>&#160;</p> <p class="MsoNormal" style="margin-left: 7.1pt">&#160;</p> <o:p><span style="font-size: 9pt; color: #454647; font-family: Arial">&#160;</span></o:p> <p> <tr style="mso-yfti-irow: 3"> </tr> <td style="padding-right: 1.5pt; padding-left: 1.5pt; padding-bottom: 1.5pt; width: 24.54%; padding-top: 1.5pt" width="24%">&#160;</td> </p> <p class="MsoNormal" style="margin-left: 7.1pt"><strong><span style="font-size: 9pt; color: #454647; font-family: Arial; mso-bidi-font-size: 10.0pt">Referanseområde</span></strong></p> <o:p></o:p> <p> <td style="padding-right: 1.5pt; padding-left: 1.5pt; padding-bottom: 1.5pt; width: 74.36%; padding-top: 1.5pt" width="74%">&#160;</td> </p> <p class="MsoNormal" style="margin-left: 7.1pt"><span style="color: #454647; font-family: Arial">&#160;<span style="background: yellow; mso-highlight: yellow"><font style="background-color: #ffffff">150 – 800 nmol/l.</font></span></span></p> <o:p></o:p> <p>&#160;</p> <p class="MsoNormal" style="margin-left: 7.1pt">&#160;</p> <o:p><span style="font-size: 9pt; color: #454647; font-family: Arial">&#160;</span></o:p> <p> <tr style="mso-yfti-irow: 4"> </tr> <td style="padding-right: 1.5pt; padding-left: 1.5pt; padding-bottom: 1.5pt; width: 24.54%; padding-top: 1.5pt" width="24%">&#160;</td> </p> <p class="MsoNormal" style="margin-left: 7.1pt"><strong><span style="font-size: 9pt; color: #454647; font-family: Arial; mso-bidi-font-size: 10.0pt">Farmakologiske data</span></strong></p> <o:p></o:p> <p> <td style="padding-right: 1.5pt; padding-left: 1.5pt; padding-bottom: 1.5pt; width: 74.36%; padding-top: 1.5pt" width="74%">&#160;</td> </p> <p class="MsoNormal" style="margin-left: 7.1pt"><span style="font-family: Arial">T_1/2 ca 15 - 80 timer. Stabil likevekt ca 2 - 15 døgn.</span></p> <o:p></o:p> <p>&#160;</p> <p class="MsoNormal" style="margin-left: 7.1pt">&#160;</p> <o:p><span style="font-size: 9pt; color: #454647; font-family: Arial">&#160;</span></o:p> <p class="MsoNormal" style="margin-left: 7.1pt"><span style="color: #454647; font-family: Arial">Metaboliseres ved CYP2D6.</span></p> <o:p></o:p> <p> <tr style="mso-yfti-irow: 4"> </tr> </p> <p class="MsoNormal" style="margin-left: 7.1pt"><span style="color: #454647; font-family: Arial">Hemmende effekt på CYP2D6.</span></p> <o:p></o:p> <p> <tr style="mso-yfti-irow: 5"> </tr> <td style="padding-right: 1.5pt; padding-left: 1.5pt; padding-bottom: 1.5pt; width: 24.54%; padding-top: 1.5pt" width="24%">&#160;</td> </p> <p class="MsoNormal" style="margin-left: 7.1pt"><strong><span style="font-size: 9pt; color: #454647; font-family: Arial; mso-bidi-font-size: 10.0pt">Noen</span></strong></p> <o:p></o:p> <p> <td style="padding-right: 1.5pt; padding-left: 1.5pt; padding-bottom: 1.5pt; width: 74.36%; padding-top: 1.5pt" width="74%">&#160;</td> </p> <p class="MsoNormal" style="margin-left: 7.1pt"><span style="color: #454647; font-family: Arial">Prolaktinhemmere – gjensidig redusert effekt.</span></p> <o:p></o:p> <p>&#160;</p> <p class="MsoNormal" style="margin-left: 7.1pt"><strong><span style="font-size: 9pt; color: #454647; font-family: Arial; mso-bidi-font-size: 10.0pt">viktige interaksjoner</span></strong></p> <o:p></o:p> <p> <tr style="mso-yfti-irow: 5"> </tr> </p> <p class="MsoNormal" style="margin-left: 7.1pt"><span style="font-size: 9pt; color: #454647; font-family: Arial; mso-bidi-font-size: 10.0pt; mso-bidi-font-weight: bold">www.interaksjoner.no</span></p> <o:p></o:p> <p class="MsoNormal" style="margin-left: 7.1pt"><span style="color: #454647; font-family: Arial">Levedopapreparater/dopaminagonister<strong style="mso-bidi-font-weight: normal"> – </strong>gjensidig redusert effekt.</span></p> <o:p></o:p> <p> <tr style="mso-yfti-irow: 5"> </tr> </p> <p class="MsoNormal" style="margin-left: 7.1pt"><span style="color: #454647; font-family: Arial">TCA<strong style="mso-bidi-font-weight: normal"> –</strong> økt konsentrasjon av TCA.</span></p> <o:p></o:p> <p> <tr style="mso-yfti-irow: 6; mso-yfti-lastrow: yes"> </tr> <td style="padding-right: 1.5pt; padding-left: 1.5pt; padding-bottom: 1.5pt; width: 24.54%; padding-top: 1.5pt" width="24%">&#160;</td> </p> <p class="MsoNormal" style="margin-left: 7.1pt"><strong><span style="font-size: 9pt; color: #454647; font-family: Arial; mso-bidi-font-size: 10.0pt">Kommentarer</span></strong></p> <o:p></o:p> <p> <td style="padding-right: 1.5pt; padding-left: 1.5pt; padding-bottom: 1.5pt; width: 74.36%; padding-top: 1.5pt" width="74%">&#160;</td> </p> <p class="MsoNormal" style="margin-left: 7.1pt"><span style="color: #454647; font-family: Arial">Førstegenerasjons antipsykotika, høydose.</span></p> <o:p></o:p> <p>&#160;</p> <p class="MsoNormal" style="margin-left: 7.1pt">&#160;</p> <o:p><strong><span style="font-size: 9pt; color: #454647; font-family: Arial; mso-bidi-font-size: 10.0pt">&#160;</span></strong></o:p> <p class="MsoNormal" style="margin-left: 7.1pt"><span style="color: #454647; font-family: Arial">Uttalt sederende effekt, samt antikolinerg, antiadrenerg og antihistaminerg effekt.</span></p> <o:p></o:p> <p class="MsoNormal" style="margin-left: 7.1pt">&#160;</p> <o:p><span style="font-family: Arial; mso-font-kerning: 18.0pt">&#160;</span></o:p>